

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OK TO ENTER: /SMc/ (09/29/2009))	
In re Patent Application of)	MAIL STOP RCE
Yuichi ITO et al.)	Group Art Unit: 1796
Application No.: 10/584,46	1	Examiner: Sanza L. McCLENDON
Filed: June 22, 2006)	Confirmation No.: 3314
For: CATIONIC POLYM COMPOSITION	ERIZABLE RESIN)	

DECLARATION UNDER 37 C.F.R. § 1.132

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

- I, Yuichi Ito, declare the following:
- **(1)** I am a Japanese citizen and have the following mailing address: c/o MITSUI CHEMICALS, INC., 580-32, Nagaura, Sodegaura-shi, Chiba 2990265, Japan
- (2) I graduated from Science University of Tokyo, Department of industrial chemistry. In March 1993, I received a degree of Master in Department of industrial chemistry, in Science University of Tokyo.
- (3) I have been an employee of MITSUI Chemicals Ltd. (hereinafter "Mitsui Chemicals, Inc.") since April 1993, and have been assigned to Mobara factory. Since June 2002, I am currently engaged in the research and development of adhesives.
- **(4)** I have read and am familiar with the above-identified United States patent application filed on June 22, 2006, Office Actions and cited references therein. OK TO ENTER: /SMc/ (09/29/2009)

Buchanan Ingersoll & Rooney PC

(5) The following experiments were conducted by me or under my direct supervision:

Experiments

Reference Examples 1 and 2 were prepared in the same matter as described in Example 1 of the present specification, except that iodonium salt of diphenyliodonium and tris(trifluoromethanesulfonyl)methyde, and ADEKA OPTOMER SP170 (produced by ADEKA Corporation) were used in Reference Examples 1 and 2, respectively, instead of PHODORSIL PHOTOINITIATOR 2074. Reference Examples 1 and 2 were evaluated in terms of curability in the same manner as described in the Example of the present specification, and the results are summarized in the following table together with Example 1 of the present specification:

Table A

	Name of Formulated Components	Note	Example 1 of the specification	Reference Example 1	Reference Example 2
(A)	3 — ethyl — 3-phenoxy methyl oxetane	_	94.0	94.0	94.0
(B)	RHODORSIL PHOTOINITIATOR 2074	Iodonium salt	1.6		
	Diphenyliodonium tris(trifuruolometane sulfonyl) methyde	Iodonium salt		1.1	
(B')	ADEKA OPTOMER SP170	Sulfonium salt (amount of effective ingredient: 50%)			4.0 (2.0)
(C)	Iso-buthyl vinyl ether	_	6.0	6.0	6.0
Evalua- tion item	Curability		0	0	Δ

[RHODORSIL PHOTOINITIATOR 2074]

$$\begin{bmatrix} F & F & F \\ F & F & F \end{bmatrix}_{A}^{\Theta}$$

[Diphenyliodonium Tris(trifuruolometanesulfonyl)methyde]

[ADEKA OPTOMER SP170]

$$\begin{array}{c} \mathsf{B} \\ \mathsf{S} \\ \mathsf{D} \\ \mathsf{F}_{6} \\ \mathsf{F}_{7} \\ \mathsf{F}_$$

As can be seen from the data in the above table, Reference Example 1 and Example 1, which employed an iodonium salt as the compound (B), provided curability superior to Reference Example 2, which employed a sulfonium salt.

Attorney's Docket No. 1000023-000111 Application No. 10/584,461

Page 4

I further declare that all statements made herein of my own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

R_v.

Yuich